Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 212
Filter
1.
Dysphagia ; 39(4): 623-631, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38285232

ABSTRACT

Hiatus hernia (HH) is a prevalent endoscopic finding in clinical practice, frequently co-occurring with esophageal disorders, yet the prevalence and degree of association remain uncertain. We aim to investigate HH's frequency and its suspected association with esophageal disorders. We reviewed endoscopic reports of over 75,000 consecutive patients who underwent gastroscopy over 12 years in two referral centers. HH was endoscopically diagnosed. We derived data on clinical presentation and a comprehensive assessment of benign and malignant esophageal pathologies. We performed multiple regression models to identify esophageal sequela associated with HH. The overall frequency of HH was (16.8%); the majority (89.5%) had small HHs (<3 cm). Female predominance was documented in HH patients, who were significantly older than controls (61.1±16.5 vs. 52.7±20.0; P < 0.001). The outcome analysis of esophageal pathology revealed an independent association between HH, regardless of its size, and erosive reflux esophagitis (25.7% vs. 6.2%; OR = 3.8; P < 0.001) and Barrett's esophagus (3.8% vs. 0.7%; OR = 4.7, P < 0.001). Furthermore, following rigorous age and sex matching, in conjunction with additional multivariable analyses, large HHs were associated with higher rates of benign esophageal strictures (3.6% vs. 0.3%; P < 0.001), Mallory Weiss syndrome (3.6% vs. 2.1%; P = 0.01), and incidents of food impactions (0.9% vs. 0.2%; P = 0.014). In contrast, a lower rate of achalasia was noted among this cohort (0.55% vs. 0%; P = 0.046). Besides reflux-related esophageal disorders, we outlined an association with multiple benign esophageal disorders, particularly in patients with large HHs.


Subject(s)
Hernia, Hiatal , Humans , Hernia, Hiatal/complications , Hernia, Hiatal/epidemiology , Female , Male , Middle Aged , Aged , Big Data , Adult , Prevalence , Esophageal Diseases/epidemiology , Esophageal Diseases/complications , Esophageal Diseases/etiology , Barrett Esophagus/complications , Barrett Esophagus/epidemiology , Gastroscopy/statistics & numerical data , Retrospective Studies , Esophagitis, Peptic/epidemiology , Esophagitis, Peptic/complications , Esophagitis, Peptic/diagnosis , Data Analysis
2.
Cancer Epidemiol Biomarkers Prev ; 30(11): 2088-2095, 2021 11.
Article in English | MEDLINE | ID: mdl-34497088

ABSTRACT

BACKGROUND: It remains open whether gastric precancerous lesions are associated with an elevated risk of pancreatic cancer. Our aim was to investigate the association between gastric mucosal status and pancreatic cancer risk. METHODS: Patients with gastric biopsies [normal, minor changes, superficial gastritis, and atrophic gastritis/intestinal metaplasia/dysplasia (AG/IM/Dys)] from the Swedish histopathology registers during 1979 to 2011 were included. Cross-linkages with several nationwide registries allowed complete follow-up and identification of pancreatic cancer cases until 2014. Standardized incidence ratios (SIR) and HRs were estimated. RESULTS: During 3,438,248 person-years of follow-up with 318,653 participants, 3,540 cases of pancreatic cancer were identified. The same pattern of excess risk of pancreatic cancer compared with the general population was observed across all groups: a peak of 12- to 21-fold excess risk in the first year after biopsy [e.g., normal: SIR = 17.4; 95% confidence interval (CI), 15.7-19.3; AG/IM/Dys: SIR = 11.5; 95% CI, 9.9-13.4], which dropped dramatically during the second and third years, followed by 20% to 30% increased risk after the third year (e.g., normal: SIR = 1.2; 95% CI, 1.1-1.4; AG/IM/Dys: SIR = 1.3; 95% CI, 1.1-1.5). However, no significant excess risk was observed with the normal gastric mucosa as reference. CONCLUSIONS: This unique, large pathologic cohort study did not find evidence that abnormal gastric mucosal status is causally associated with a long-term pancreatic cancer risk. However, a highly increased short-term risk was observed for people undergoing gastroscopy with biopsy sampling compared with the general population. IMPACT: Further studies for a long-term risk of pancreatic cancer in patients with gastric biopsies are needed, with further adjustments.


Subject(s)
Gastric Mucosa/pathology , Pancreatic Neoplasms/epidemiology , Precancerous Conditions/pathology , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Gastroscopy/statistics & numerical data , Humans , Male , Middle Aged , Pancreatic Neoplasms/pathology , Proportional Hazards Models , Registries , Retrospective Studies , Sweden/epidemiology
3.
Medicine (Baltimore) ; 100(2): e24055, 2021 Jan 15.
Article in English | MEDLINE | ID: mdl-33466161

ABSTRACT

ABSTRACT: Magnetic foreign bodies ingestion is a special cause for attending emergency department. Here, we aim to analyze the characteristics and treatments of children who ingested magnetic foreign bodies (Buckyballs). Data were collected from children who ingested Buckyballs between February 2017 and October 2019. A retrospective analysis was performed to summarize the experiences of conservative treatment, gastroscopy and surgery when dealing with Buckyballs ingestion.A total of 49 patients with buckyballs ingestion were identified, of whom 11 underwent conservative treatments, 6 underwent gastroscopy, and 32 underwent surgery. Among such individuals, eight patients (72.7%) had a successful conservative treatment (number of Buckyballs [NB]: 3.5[IQR: 2.0-4.0]); four patients (66.7%) had Buckyballs successfully removed by gastroscopy (NB: 3.5[IQR: 3.0-5.5]); 16 asymptomatic (50%) patients (NB: 4.0[IQR: 3.0-8.0]) and 16 symptomatic (50%) patients (NB: 8.5 [IQR: 6.25-11.75]) received emergency surgery. Compared to patients who received conservative treatment, the number of ingested Buckyballs was significantly higher in patients who received surgery or gastroscopy (7.0 [IQR: 3.0-10.75] vs 3.5 [IQR: 2.0-4.0], P < .05). The risk of intestinal perforation was significantly higher in symptomatic patients (P < .05) compared to asymptomatic patients.Gastroscopy is recommended when Buckyballs are in the stomach or esophagus. In asymptomatic patients, conservative treatment can be considered for 4 to 6 days. Patients failing conservative treatment, or those who are symptomatic should undergo emergency surgery.


Subject(s)
Abdomen , Conservative Treatment/statistics & numerical data , Emergency Treatment/statistics & numerical data , Foreign Bodies/therapy , Gastroscopy/statistics & numerical data , Magnets , Child , Child, Preschool , Emergency Service, Hospital , Female , Humans , Infant , Male , Retrospective Studies , Treatment Outcome
4.
Gastroenterology ; 160(4): 1106-1117.e3, 2021 03.
Article in English | MEDLINE | ID: mdl-33220252

ABSTRACT

BACKGROUND & AIMS: Helicobacter pylori eradication and endoscopic surveillance of gastric precancerous lesions are strategies to reduce gastric cancer (GC) risk. To our knowledge, this study is the longest prospective cohort of an H pylori eradication trial in a Hispanic population. METHODS: A total of 800 adults with precancerous lesions were randomized to anti-H pylori treatment or placebo. Gastric biopsy samples taken at baseline and 3, 6, 12, 16, and 20 years were assessed by our Correa histopathology score. A generalized linear mixed model with a participant-level random intercept was used to estimate the effect of H pylori status on the score over time. Logistic regression models were used to estimate progression by baseline diagnosis and to estimate GC risk by intestinal metaplasia (IM) subtype and anatomic location. RESULTS: Overall, 356 individuals completed 20 years of follow-up. Anti-H pylori therapy (intention-to-treat) reduced progression of the Correa score (odds ratio [OR], 0.59; 95% confidence interval [CI], 0.38-0.93). H pylori-negative status had a beneficial effect on the score over time (P = .036). Among individuals with IM (including indefinite for dysplasia) at baseline, incidence rates per 100 person-years were 1.09 (95% CI, 0.85-1.33) for low-grade/high-grade dysplasia and 0.14 (95% CI, 0.06-0.22) for GC. Incomplete-type (vs complete-type) IM at baseline presented higher GC risk (OR, 13.4; 95% CI, 1.8-103.8). Individuals with corpus (vs antrum-restricted) IM showed an OR of 2.1 (95% CI, 0.7-6.6) for GC. CONCLUSIONS: In a high-GC-risk Hispanic population, anti-H pylori therapy had a long-term beneficial effect against histologic progression. Incomplete IM is a strong predictor of GC risk.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Gastric Mucosa/pathology , Helicobacter Infections/drug therapy , Precancerous Conditions/epidemiology , Stomach Neoplasms/prevention & control , Adult , Aged , Biopsy , Colombia/epidemiology , Disease Progression , Female , Follow-Up Studies , Gastric Mucosa/diagnostic imaging , Gastric Mucosa/microbiology , Gastroscopy/statistics & numerical data , Helicobacter Infections/microbiology , Helicobacter Infections/pathology , Helicobacter pylori/isolation & purification , Humans , Incidence , Male , Metaplasia/diagnosis , Metaplasia/epidemiology , Metaplasia/microbiology , Metaplasia/pathology , Middle Aged , Precancerous Conditions/diagnosis , Precancerous Conditions/microbiology , Precancerous Conditions/pathology , Prospective Studies , Risk Factors , Stomach Neoplasms/epidemiology , Stomach Neoplasms/microbiology , Stomach Neoplasms/pathology , Treatment Outcome
5.
Clin Cancer Res ; 27(3): 719-728, 2021 02 01.
Article in English | MEDLINE | ID: mdl-33172897

ABSTRACT

PURPOSE: Gastric cancer remains the leading cause of cancer-related deaths in Northeast Asia. Population-based endoscopic screenings in the region have yielded successful results in early detection of gastric tumors. Endoscopic screening rates are continuously increasing, and there is a need for an automatic computerized diagnostic system to reduce the diagnostic burden. In this study, we developed an algorithm to classify gastric epithelial tumors automatically and assessed its performance in a large series of gastric biopsies and its benefits as an assistance tool. EXPERIMENTAL DESIGN: Using 2,434 whole-slide images, we developed an algorithm based on convolutional neural networks to classify a gastric biopsy image into one of three categories: negative for dysplasia (NFD), tubular adenoma, or carcinoma. The performance of the algorithm was evaluated by using 7,440 biopsy specimens collected prospectively. The impact of algorithm-assisted diagnosis was assessed by six pathologists using 150 gastric biopsy cases. RESULTS: Diagnostic performance evaluated by the AUROC curve in the prospective study was 0.9790 for two-tier classification: negative (NFD) versus positive (all cases except NFD). When limited to epithelial tumors, the sensitivity and specificity were 1.000 and 0.9749. Algorithm-assisted digital image viewer (DV) resulted in 47% reduction in review time per image compared with DV only and 58% decrease to microscopy. CONCLUSIONS: Our algorithm has demonstrated high accuracy in classifying epithelial tumors and its benefits as an assistance tool, which can serve as a potential screening aid system in diagnosing gastric biopsy specimens.


Subject(s)
Deep Learning , Gastric Mucosa/pathology , Image Interpretation, Computer-Assisted/methods , Pathologists/statistics & numerical data , Stomach Neoplasms/diagnosis , Adult , Aged , Aged, 80 and over , Biopsy/statistics & numerical data , Feasibility Studies , Female , Gastric Mucosa/diagnostic imaging , Gastroscopy/statistics & numerical data , Humans , Image Interpretation, Computer-Assisted/statistics & numerical data , Male , Middle Aged , Observer Variation , Prospective Studies , Retrospective Studies , Sensitivity and Specificity , Stomach Neoplasms/pathology
6.
J Gastrointest Cancer ; 52(1): 57-67, 2021 Mar.
Article in English | MEDLINE | ID: mdl-32964322

ABSTRACT

PURPOSE: Gastric schwannomas (GSs) are rare mesenchymal neoplasms of the gastrointestinal tract. Diagnosis is often achieved postoperatively, based on pathology reports of retrieved specimens. The aim of the present study is to follow up all patients with gastric schwannoma (Gs) undergoing endoscopic, partial, or more extended surgery and to evaluate the appearance of local or distant recurrence. METHODS: A PubMed, Cochrane, and Embase systematic review of the literature has been performed. Original papers, review articles, and case reports published between 1988 and 2019 were considered eligible. All the studies who met the inclusion criteria were analyzed. Statistical analysis of data has been performed using GraphPad Prism 7 software. RESULTS: Three hundred twenty-eight articles were found, and a total of 102 were included and analyzed in depth. Fifty-three papers reported the follow-up information, ranging from 1 to 417 months across different studies. Among them, 31 patients underwent endoscopic removal of the gastric lesions; 140 patients underwent local surgery, including wedge resection or partial gastrectomy; and 148 patients underwent subtotal or total gastrectomy. The median follow-up was of 27-38-33 months, respectively. No recurrence or distant metastasis was detected in the endoscopy group. Among local surgery group, liver metastasis was reported in one case; in extended surgery group, one patient died for multiple liver metastases. CONCLUSIONS: Local or more extended surgery involved a larger cohort of patients and reported satisfactory long-term results compared with endoscopy group. Surgery in absence of a definite preoperative diagnosis is considered the gold standard treatment for resectable Gs.


Subject(s)
Gastrectomy/methods , Liver Neoplasms/epidemiology , Neoplasm Recurrence, Local/epidemiology , Neurilemmoma/surgery , Stomach Neoplasms/surgery , Follow-Up Studies , Gastrectomy/statistics & numerical data , Gastroscopy/methods , Gastroscopy/statistics & numerical data , Humans , Incidental Findings , Liver Neoplasms/diagnosis , Liver Neoplasms/prevention & control , Liver Neoplasms/secondary , Neoplasm Recurrence, Local/prevention & control , Neurilemmoma/diagnosis , Neurilemmoma/epidemiology , Neurilemmoma/secondary , Stomach/innervation , Stomach/pathology , Stomach/surgery , Stomach Neoplasms/diagnosis , Stomach Neoplasms/epidemiology , Stomach Neoplasms/pathology , Treatment Outcome
7.
Int J Cancer ; 148(1): 106-114, 2021 01 01.
Article in English | MEDLINE | ID: mdl-32930401

ABSTRACT

In our study, we evaluated the effectiveness of upper gastrointestinal (GI) endoscopy as an instrument for early gastric cancer (GC) detection in Lynch syndrome (LS) patients by analyzing data from the registry of the German Consortium for Familial Intestinal Cancer. In a prospective, multicenter cohort study, 1128 out of 2009 registered individuals with confirmed LS underwent 5176 upper GI endoscopies. Compliance was good since 77.6% of upper GI endoscopies were completed within the recommended interval of 1 to 3 years. Forty-nine GC events were observed in 47 patients. MLH1 (n = 21) and MSH2 (n = 24) mutations were the most prevalent. GCs in patients undergoing regular surveillance were diagnosed significantly more often in an early-stage disease (UICC I) than GCs detected through symptoms (83% vs 25%; P = .0231). Thirty-two (68%) patients had a negative family history of GC. The median age at diagnosis was 51 years (range 28-66). Of all GC patients, 13 were diagnosed at an age younger than 45. Our study supports the recommendation of regular upper GI endoscopy surveillance for LS patients beginning no later than at the age of 30.


Subject(s)
Colorectal Neoplasms, Hereditary Nonpolyposis/complications , Early Detection of Cancer/methods , Gastroscopy/statistics & numerical data , Stomach Neoplasms/diagnosis , Adult , Age Factors , Aged , Colorectal Neoplasms, Hereditary Nonpolyposis/genetics , Early Detection of Cancer/standards , Early Detection of Cancer/statistics & numerical data , Evaluation Studies as Topic , Gastric Mucosa/diagnostic imaging , Gastric Mucosa/pathology , Gastroscopy/standards , Genetic Predisposition to Disease , Germany/epidemiology , Humans , Male , Middle Aged , MutL Protein Homolog 1/genetics , MutS Homolog 2 Protein/genetics , Mutation , Neoplasm Staging , Patient Compliance/statistics & numerical data , Practice Guidelines as Topic , Prospective Studies , Stomach Neoplasms/epidemiology , Stomach Neoplasms/genetics , Stomach Neoplasms/pathology
8.
Neth J Med ; 78(4): 161-166, 2020 07.
Article in English | MEDLINE | ID: mdl-32641540

ABSTRACT

PURPOSE: To determine whether the use of salicylates is a predictive factor for detecting explanatory pathology during gastroscopy or colonoscopy procedures in patients with iron deficiency anaemia (IDA). METHODS: This retrospective study included patients who underwent a gastroscopy and/or a colonoscopyto determine the cause of IDA at Treant Healthcare, hospital location Scheper in Emmen, the Netherlands, between 2010 and 2016. The study compared two groups. The first group consisted of patients who were not taking antithrombotics at the time of, and during the last six months prior to, the endoscopy. The second group consisted of patients who used salicylates at the time of, and during the last six months prior, to the endoscopy. Data were collected on whether and which explanatory pathology was found in the endoscopic evaluation. RESULTS: In total, 464 patients were included, of whom, 174 were using a salicylate and 290 were not. In 41.2% of the patients, explanatory pathology was found, which was not significantly different between the two groups with univariate analysis (p = 0.207). However, the patients in the group of salicylate users were significantly older and more often male. When correcting for these differences in group characteristics during multivariate analysis, the use of salicylates was found to be a negative predictive factor for finding explanatory pathology (p < 0.001; OR 2.307). CONCLUSION: When determining the chance of finding explanatory pathology during endoscopic evaluation in patients with IDA, the use of salicylates should be taken into account as a negative predictive factor for finding explanatory pathology during endoscopic evaluation.


Subject(s)
Anemia, Iron-Deficiency/diagnosis , Colonoscopy/statistics & numerical data , Fibrinolytic Agents/therapeutic use , Gastroscopy/statistics & numerical data , Salicylates/therapeutic use , Age Factors , Aged , Female , Humans , Male , Middle Aged , Netherlands , Predictive Value of Tests , Retrospective Studies , Sex Factors
10.
Gastroenterol Hepatol ; 43(10): 589-597, 2020 Dec.
Article in English, Spanish | MEDLINE | ID: mdl-32674879

ABSTRACT

INTRODUCTION: In a previous study we demonstrated that a simple training programme improved quality indicators of Oesophagogastroduodenoscopy (OGD) achieving the recommended benchmarks. However, the long-term effect of this intervention is unknown. The aim of this study was to assess the quality of OGDs performed 3 years after of having completed a training programme. MATERIAL AND METHODS: A comparative study of 2 cohorts was designed as follows: Group A included OGDs performed in 2016 promptly after a training programme and Group B with OGDs performed from January to March 2019, this group was also divided into 2 subgroups: subgroup B1 of Endoscopists who had participated in the previous training programme and subgroup B2 of Endoscopists who had not. The intra-procedure quality indicators proposed by ASGE-ACG were used. RESULTS: A total of 1236 OGDs were analysed, 600 from Group A and 636 from Group B (439 subgroup B1 and 197 subgroup B2). The number of complete examinations was lower in Group B (566 [94.3%] vs. 551 [86.6%]; p<0.001). A significant decrease was observed in nearly all quality indicators and they did not reach the recommended benchmarks: retroflexion in the stomach (96% vs. 81%; p<0.001); Seattle biopsy protocol (86% vs. 50%; p=0.03), description of the upper GI bleeding lesion (100% vs. 62%; p<0.01), sufficient intestinal biopsy specimens (at least 4) in suspected coeliac disease (92.5% vs. 18%; p<0.001), photo documentation of the lesion (94% vs. 90%; p<0.05). Regarding the overall assessment of the procedure (including correct performance and adequate photo documentation), a significant decrease was also observed (90.5% vs. 62%; p<0.001). There were no differences between subgroups B1 and B2. CONCLUSIONS: The improvement observed in 2016 after a training programme did not prevail after 3 years. In order to keep the quality of OGDs above the recommended benchmarks, it is necessary to implement continuous training programmes.


Subject(s)
Benchmarking , Duodenoscopy/standards , Esophagoscopy/standards , Gastroscopy/standards , Quality Indicators, Health Care/standards , Biopsy/standards , Celiac Disease/pathology , Cohort Studies , Duodenoscopy/education , Duodenoscopy/statistics & numerical data , Esophagoscopy/education , Esophagoscopy/statistics & numerical data , Gastrointestinal Hemorrhage/diagnostic imaging , Gastroscopy/education , Gastroscopy/statistics & numerical data , Humans , Intestines/pathology , Photography , Program Development , Reference Standards , Societies, Medical , Time Factors
11.
World J Gastroenterol ; 26(20): 2618-2631, 2020 May 28.
Article in English | MEDLINE | ID: mdl-32523315

ABSTRACT

BACKGROUND: Persistent Helicobacter pylori (H. pylori) infection causes chronic inflammation, atrophy of the gastric mucosa, and a high risk of developing gastric cancer. In recent years, awareness of eradication therapy has increased in Japan. As H. pylori infections decrease, the proportion of gastric cancers arising from H. pylori uninfected gastric mucosa will increase. The emergence of gastric cancer arising in H. pylori uninfected patients though rarely reported, is a concern to be addressed and needs elucidation of its clinicopathological features. AIM: To evaluate the clinicopathological features of early gastric cancer in H. pylori-uninfected patients. METHODS: A total of 2462 patients with 3375 instances of early gastric cancers that were treated by endoscopic submucosal dissection were enrolled in our study between May 2000 and September 2019. Of these, 30 lesions in 30 patients were diagnosed as H. pylori-uninfected gastric cancer (HpUIGC). We defined a patient as H. pylori-uninfected using the following three criteria: (1) The patient did not receive treatment for H. pylori, which was determined by investigating medical records and conducting patient interviews; (2) Lack of endoscopic atrophy; and (3) The patient was negative for H. pylori after being tested at least twice using various diagnostic methods, including serum anti-H. pylori-IgG antibody, urease breath test, rapid urease test, and microscopic examination. RESULTS: The frequency of HpUIGC was 1.2% (30/2462) for the patients in our study. The study included 19 males and 11 females with a mean age of 59 years. The location of the stomach lesions was divided into three sections; upper third (U), middle third (M), lower third (L). Of the 30 lesions, 15 were U, 1 was M, and 14 were L. Morphologically, 17 lesions were protruded and flat elevated type (0-I, 0-IIa, 0-IIa + IIc), and 13 lesions were flat and depressed type (0-IIb, 0-IIc). The median tumor diameter was 8 mm (range 2-98 mm). Histological analysis revealed that 22 lesions (73.3%) were differentiated type.The HpUIGC lesions were classified into fundic gland type adenocarcinoma (7 cases), foveolar type well-differentiated adenocarcinoma (8 cases), intestinal phenotype adenocarcinoma (7 cases), and pure signet-ring cell carcinoma (8 cases). Among 30 HpUIGCs, 24 lesions (80%) were limited to the mucosa; wherein, the remaining 6 lesions showed submucosal invasion. One of the submucosal invasive lesions showed more than 500 µm invasion. The mucin phenotype analysis identified 7 HpUIGC with intestinal phenotype and 23 with gastric phenotype. CONCLUSION: We elucidated the clinicopathological characteristics of HpUIGC, revealing recognition not only undifferentiated-type but also differentiated-type. In addition, intestinal phenotype tumors were also observed and could be an important tip.


Subject(s)
Adenocarcinoma/epidemiology , Carcinoma, Signet Ring Cell/epidemiology , Gastric Mucosa/pathology , Stomach Neoplasms/epidemiology , Adenocarcinoma/diagnosis , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Aged , Carcinoma, Signet Ring Cell/diagnosis , Carcinoma, Signet Ring Cell/pathology , Carcinoma, Signet Ring Cell/surgery , Endoscopic Mucosal Resection/statistics & numerical data , Female , Gastric Mucosa/diagnostic imaging , Gastric Mucosa/surgery , Gastroscopy/statistics & numerical data , Helicobacter Infections/diagnosis , Helicobacter Infections/microbiology , Helicobacter pylori/isolation & purification , Humans , Male , Middle Aged , Stomach Neoplasms/diagnosis , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery , Tumor Burden
12.
Cancer Prev Res (Phila) ; 13(9): 773-782, 2020 09.
Article in English | MEDLINE | ID: mdl-32561562

ABSTRACT

Gastric carcinoma (GC) disproportionately affects Asian Americans. We examined whether history of upper gastrointestinal (GI) endoscopy was associated with lower stage at GC diagnosis among Asian Americans and whether origin of providers influenced referral for endoscopy. We employed Surveillance Epidemiology and End Results-Medicare data on Asian Americans diagnosed with GC in 2004-2013 (n = 1,554). Stage distribution, GI conditions at diagnosis, and history of endoscopy were compared between Asian ethnic groups. Multivariate logistic regression adjusting for age, sex, poverty level, tumor location, and histology was used to examine the association of ethnicity and endoscopic history with stage I disease at diagnosis of GC. Koreans were more likely to be diagnosed with stage I, T1a GC and have prior history of endoscopy, compared with other Asian ethnicities (24% vs. 8% for stage I, T1a; 40% vs. 15% for endoscopy). Patients with primary care providers of concordant ethnic origin were more likely to have history of endoscopy. Asian American patients with GC with history of endoscopy were more likely to be diagnosed with GC at stage I disease (adjusted OR, 3.07; 95% confidence interval, 2.34-4.02). Compared with other Asian Americans, Koreans were diagnosed with GC at earlier stages owing to common history of endoscopy, which was more often undergone by patients with primary care providers of concordant ethnic origin. Overall, upper GI endoscopy was associated with early detection of GC in Asian Americans. Novelty and Impact. It is well-established that Asian Americans in the United States are disproportionately affected by gastric cancer. In our study we found that Asian American patients treated by physicians of similar ethnic background are more likely to undergo upper GI endoscopy in the United States, leading to early detection of gastric cancer and longer survival. Given this, targeted endoscopic screening in Asian Americans should be considered for early detection of GC.


Subject(s)
Carcinoma/mortality , Gastroscopy/statistics & numerical data , Healthcare Disparities/statistics & numerical data , Mass Screening/statistics & numerical data , Stomach Neoplasms/mortality , Aged , Aged, 80 and over , Asian/statistics & numerical data , Carcinoma/diagnosis , Carcinoma/economics , Female , Healthcare Disparities/economics , Humans , Male , Mass Screening/economics , Medicare/economics , Medicare/statistics & numerical data , Neoplasm Staging , Physicians, Primary Care/statistics & numerical data , Poverty/statistics & numerical data , Referral and Consultation/economics , Referral and Consultation/statistics & numerical data , SEER Program/statistics & numerical data , Stomach/diagnostic imaging , Stomach/pathology , Stomach Neoplasms/diagnosis , Stomach Neoplasms/economics , Stomach Neoplasms/therapy , United States/epidemiology
13.
Clin Transl Gastroenterol ; 11(4): e00167, 2020 04.
Article in English | MEDLINE | ID: mdl-32352683

ABSTRACT

INTRODUCTION: The prognosis of Cronkhite-Canada syndrome (CCS) is considered poor. Despite the recent therapeutic improvements, the survival outcomes and prognostic factors have been less studied. This study aimed to investigate the long-term clinical and endoscopic outcomes of CCS. METHODS: Thirty-one patients diagnosed since 1999 and followed up for over 6 months were included. Data regarding survival outcomes, clinical symptoms, endoscopic findings, and treatment were collected and analyzed. R (version 3.6.1) was used to perform the survival analyses. RESULTS: The median (interquartile range) follow-up time was 42.5 (19.5-85.8) months. The 5-year overall survival (OS) was 87.4%. The maximum gastric polyp size over 2 cm was associated with worse OS (Hazard ratio [HR]: 18, 95% confidence interval [CI]: 1.6-210, P = 0.021). The 3-year relapse-free survival (RFS) after corticosteroid treatment was 66.8%. Age older than 60 years (HR: 7.0, 95% CI: 1.5-33.0, P = 0.015) and maximum gastric polyp size over 2 cm (HR: 6.0, 95% CI: 1.6-23.0, P = 0.009) were associated with worse RFS. Twenty-three patients received follow-up endoscopic examinations, with a median (interquartile range) follow-up time of 29.0 (14.0-53.5) months. Eight (34.8%) and 12 (52.2%) patients achieved complete remission under gastroscopy and colonoscopy, respectively. Colonic lesions showed a tendency of earlier responses compared with gastric lesions (25.0 [11.3-39.8] months vs 31.0 [21.0-39.8] months). DISCUSSION: Patients with CCS usually responded well to glucocorticoids with a fairly good 5-year survival rate. Large gastric polyp was associated with worse OS and RFS, whereas age older than 60 years was another predictor for worse RFS. Diffuse gastrointestinal lesions partly or completely resolved after treatment, and colonic lesions showed a better response than gastric lesions.


Subject(s)
Adenomatous Polyps/mortality , Colonoscopy/statistics & numerical data , Gastroscopy/statistics & numerical data , Glucocorticoids/therapeutic use , Intestinal Polyposis/mortality , Stomach Neoplasms/mortality , Adenomatous Polyps/diagnosis , Adenomatous Polyps/drug therapy , Adenomatous Polyps/pathology , Age Factors , Colon/diagnostic imaging , Colon/pathology , Disease-Free Survival , Female , Follow-Up Studies , Gastric Mucosa/diagnostic imaging , Gastric Mucosa/pathology , Humans , Intestinal Mucosa/diagnostic imaging , Intestinal Mucosa/pathology , Intestinal Polyposis/diagnosis , Intestinal Polyposis/drug therapy , Intestinal Polyposis/pathology , Male , Middle Aged , Prognosis , Recurrence , Retrospective Studies , Risk Assessment/statistics & numerical data , Risk Factors , Stomach/diagnostic imaging , Stomach/pathology , Stomach Neoplasms/diagnosis , Stomach Neoplasms/drug therapy , Stomach Neoplasms/pathology , Survival Rate
14.
Fam Cancer ; 19(4): 337-346, 2020 10.
Article in English | MEDLINE | ID: mdl-32385704

ABSTRACT

INTRODUCTION: This nationwide study assessed the impact of Lynch syndrome-related risk management guidelines on clinicians' recommendations of risk management strategies to carriers of pathogenic variants in mismatch repair genes and the extent to which carriers took up strategies in concordance with guidelines. MATERIALS AND METHODS: Clinic files of 464 carriers (with and without colorectal cancer) were audited for carriers who received their genetic testing results in July 2008-July 2009 (i.e. before guideline release), July 2010-July 2011 and July 2012-July 2013 (both after guideline release) at 12 familial cancer clinics (FCCs) to ascertain the extent to which carriers were informed about risk management in accordance with guidelines. All carriers captured by the audit were invited to participate in interviews; 215 were interviewed to assess adherence to recommended risk management guidelines. RESULTS: The rates of documentation in clinic files increased significantly from pre- to post-guideline for only two out of eight risk management strategies. The strategies with the highest compliance of carriers post-guidelines were: uptake of one or two-yearly colonoscopy (87%), followed by hysterectomy to prevent endometrial cancer (68%), aspirin as risk-reducing medication (67%) and risk-reducing salpingo-oophorectomy (63%). Interrater reliability check for all guidelines showed excellent agreement (k statistics = 0.89). CONCLUSION: These results indicate that there is scope to further increase provision of advice at FCCs to ensure that all carriers receive recommendations about evidence-based risk management. A multi-pronged behaviour change and implementation science approach tailored to specific barriers is likely to be needed to achieve optimal clinician behaviours and outcomes for carriers.


Subject(s)
Colorectal Neoplasms, Hereditary Nonpolyposis/genetics , DNA Mismatch Repair/genetics , Guideline Adherence/statistics & numerical data , Heterozygote , Risk Assessment , Adult , Anticarcinogenic Agents/administration & dosage , Aspirin/administration & dosage , Colonoscopy/statistics & numerical data , Colorectal Neoplasms/genetics , Colorectal Neoplasms/prevention & control , Endometrial Neoplasms/prevention & control , Female , Gastroscopy/statistics & numerical data , Genetic Testing/standards , Humans , Hysterectomy/statistics & numerical data , Male , Medical Audit/statistics & numerical data , Middle Aged , Ovarian Neoplasms/prevention & control , Patient Compliance/psychology , Patient Compliance/statistics & numerical data , Reproducibility of Results , Salpingo-oophorectomy/statistics & numerical data , Stomach Neoplasms/prevention & control
15.
J Gastrointestin Liver Dis ; 29(1): 19-25, 2020 Mar 13.
Article in English | MEDLINE | ID: mdl-32176750

ABSTRACT

BACKGROUND AND AIM: Helicobacter pylori infection is very common worldwide, and it is associated with an important gastric pathology. Treatment of this infection is difficult and consists of the combination of two or three antibiotics. However, the rate of resistance to treatment is high. Antimicrobial resistance of Helicobacter pylori is based on its cultivation in the laboratory and testing of phenotypic susceptibility, a time-consuming, laborious method. This study aimed to detect the genetic resistance to antibiotics of Helicobacter pylori in the south-eastern region of Romania. METHODS: Ninety patients with positive rapid urease test gastric biopsy samples were tested. Genetic resistance to antibiotics (fluoroquinolone and clarithromycin) was tested by GenoType HelicoDR kit (Hain Lifescience GmbH, Germany). RESULTS: Clarithromycin resistance mutations were detected in 20% of patients, the commonest mutation in our study beeing A2147G (associated with high level of clarithromycin resistance and lower cure rates). Fluoroquinolones resistance mutations were detected in 30% of patients, and the most common mutations were D91N, D91G, and N87K. There was no correlation with patients gender or age, with the exception of fluoroquinolone resistance, which was detected more frequently in females.   Conclusions. Clarithromycin and fluoroquinolone resistance of Helicobacter pylori is moderately high in our study. There is a need for monitoring Helicobacter resistance patterns in Romania to provide data that can guide empirical treatment. This is the first published study on the genetic resistance of Helicobacter pylori in Romania.


Subject(s)
Clarithromycin/pharmacology , Drug Resistance, Bacterial/genetics , Fluoroquinolones/pharmacology , Helicobacter Infections , Helicobacter pylori , Stomach , Anti-Bacterial Agents/pharmacology , Biopsy/methods , Female , Gastroscopy/methods , Gastroscopy/statistics & numerical data , Helicobacter Infections/diagnosis , Helicobacter Infections/epidemiology , Helicobacter Infections/physiopathology , Helicobacter pylori/drug effects , Helicobacter pylori/genetics , Helicobacter pylori/isolation & purification , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Point Mutation , Romania/epidemiology , Stomach/microbiology , Stomach/pathology
16.
Gut ; 69(10): 1762-1768, 2020 10.
Article in English | MEDLINE | ID: mdl-32051208

ABSTRACT

OBJECTIVES: To assess the value of endoscopic grading of gastric intestinal metaplasia (EGGIM), operative link on gastritis assessment (OLGA) and operative link on gastric intestinal metaplasia (OLGIM) on risk stratification for early gastric neoplasia (EGN) and to investigate other factors possibly associated with its development. DESIGN: Single centre, case-control study including 187 patients with EGN treated endoscopically and 187 age-matched and sex-matched control subjects. Individuals were classified according to EGGIM, OLGA and OLGIM systems. EGN risk according to gastritis stages and other clinical parameters was further evaluated. RESULTS: More patients with EGN had EGGIM of ≥5 than control subjects (68.6% vs 13.3%, p<0.001). OLGA and OLGIM stages III/IV were more prevalent in patients with EGN than in control subjects (68% vs 11%, p<0.001, and 61% vs 3%, p<0.001, respectively). The three systems were the only parameters significantly related to the risk of EGN in multivariate analysis: for EGGIM 1-4 (adjusted OR (AOR) 12.9, 95% CI 1.4 to 118.6) and EGGIM 5-10 (AOR 21.2, 95% CI 5.0 to 90.2); for OLGA I/II (AOR 5.0, 95% CI 0.56 to 44.5) and OLGA III/IV (AOR 11.1, 95% CI 3.7 to 33.1); for OLGIM I/II (AOR 11.5, 95% CI 4.1 to 32.3) and OLGIM III/IV (AOR 16.0, 95% CI 7.6 to 33.4). CONCLUSION: This study confirms the role of histological assessment as an independent risk factor for gastric cancer (GC), but it is the first study to show that an endoscopic classification of gastric intestinal metaplasia is highly associated with that outcome. After further prospective validation, this classification may be appropriate for GC risk stratification and may simplify every day practice by reducing the need for biopsies.


Subject(s)
Early Detection of Cancer , Gastroscopy , Risk Assessment , Stomach Neoplasms , Biopsy/methods , Case-Control Studies , Early Detection of Cancer/methods , Early Detection of Cancer/standards , Early Detection of Cancer/statistics & numerical data , Female , Gastroscopy/methods , Gastroscopy/statistics & numerical data , Humans , Male , Metaplasia/classification , Metaplasia/diagnosis , Metaplasia/pathology , Middle Aged , Neoplasm Staging , Portugal , Quality Improvement , Risk Assessment/methods , Risk Assessment/statistics & numerical data , Stomach Neoplasms/diagnosis , Stomach Neoplasms/pathology
17.
Digestion ; 101(5): 624-630, 2020.
Article in English | MEDLINE | ID: mdl-31336366

ABSTRACT

INTRODUCTION: The diagnosis of Helicobacter pylori infection status with white light imaging (WLI) is difficult. We evaluated the accuracies of using WLI and linked color imaging (LCI) for diagnosing H. pylori-active gastritis in a multicenter prospective study setting. METHODS: Patients who underwent esophagogastroduodenoscopy were prospectively included. The image collection process was randomized and anonymous, and the image set included 4 images with WLI or 4 images with LCI in the corpus that 5 reviewers separately evaluated. Active gastritis was defined as positive when there was diffuse redness in WLI and crimson coloring in LCI. The H. pylori infection status was determined by the urea breath test and the serum antibody test. Cases in which both test results were negative but atrophy or intestinal metaplasia was histologically confirmed were defined as past infections. The primary endpoint was the diagnostic accuracies of WLI and LCI, and the secondary endpoint was inter-observer agreement. RESULTS: Data for 127 patients were analyzed. The endoscopic diagnostic accuracy for active gastritis was 79.5 (sensitivity of 84.4 and specificity of 74.6) with WLI and 86.6 (sensitivity of 84.4 and specificity of 88.9) with LCI (p = 0.029). LCI significantly improved the accuracy in patients with past infections over WLI (36.8 in WLI and 78.9 in LCI, p < 0.01). The κ values were 0.59 in WLI and 0.70 in LCI. CONCLUSIONS: LCI is useful for endoscopic diagnosis of H. pylori-active or inactive gastritis, and it is advantageous for patients with past infections of inactive gastritis.


Subject(s)
Gastric Mucosa/diagnostic imaging , Gastritis/diagnosis , Gastroscopy/methods , Helicobacter Infections/diagnosis , Image Enhancement/methods , Adult , Aged , Aged, 80 and over , Antibodies, Bacterial/blood , Breath Tests , Color , Feasibility Studies , Female , Gastric Mucosa/microbiology , Gastric Mucosa/pathology , Gastritis/blood , Gastritis/microbiology , Gastritis/pathology , Gastroscopy/instrumentation , Gastroscopy/statistics & numerical data , Helicobacter Infections/blood , Helicobacter Infections/microbiology , Helicobacter Infections/pathology , Helicobacter pylori/immunology , Helicobacter pylori/isolation & purification , Humans , Image Enhancement/instrumentation , Male , Metaplasia/blood , Metaplasia/diagnosis , Metaplasia/microbiology , Metaplasia/pathology , Middle Aged , Narrow Band Imaging/instrumentation , Narrow Band Imaging/methods , Narrow Band Imaging/statistics & numerical data , Prospective Studies
18.
Digestion ; 101(2): 184-190, 2020.
Article in English | MEDLINE | ID: mdl-30820016

ABSTRACT

BACKGROUND AND AIM: According to several guidelines, both invasive and non-invasive tests can be used to detect Helicobacter pylori (H. pylori). Invasive methods include H. pylori culture, histological staining, rapid urease tests (RUTs) and PCR. Non-invasive methods include urease breath test, stool antigen and serum IgG testing. The aim of our study was to compare all commercially available RUTs and histology in Germany. MATERIAL AND METHODS: One hundred fifty patients were enrolled in our study, irrespective of proton pump inhibitors (PPIs) or antibiotic use. If the results of RUTs and histology were diverging, real-time PCR to detect H. pylori DNA was undertaken. RESULTS: We detected no differences in the sensitivity or specificity between the different RUTs. In PPI and/or antibiotic-treated patients, RUTs seemed to be more sensitive for the detection of H. pylori infection compared to histology. In addition to the cheaper price of RUTs, they are also quicker to process. We show that histological staining in patients with signs of gastritis is expensive and not necessary, if there are no additional histological questions besides H. pylori status. CONCLUSIONS: In conclusion, we consider RUTs to be cheap and fast alternatives to histology in patients with endoscopic signs of gastritis, independently of whether PPIs or antibiotic are used. Histological evaluation is expensive, time consuming and may be unnecessary in some cases.


Subject(s)
Breath Tests/methods , Gastritis/diagnosis , Gastroscopy/statistics & numerical data , Urease/analysis , Aged , Anti-Bacterial Agents/therapeutic use , Female , Gastritis/microbiology , Helicobacter Infections/diagnosis , Helicobacter Infections/microbiology , Helicobacter pylori , Humans , Male , Middle Aged , Predictive Value of Tests , Proton Pump Inhibitors/therapeutic use , Reproducibility of Results , Sensitivity and Specificity , Stomach/pathology
19.
Digestion ; 101(2): 191-197, 2020.
Article in English | MEDLINE | ID: mdl-30889600

ABSTRACT

BACKGROUND: Determining the depth of invasion is important when considering therapeutic strategies for early gastric cancer (EGC). We determined the effects of learning the non-extension sign, that is, an index of T1b2 in EGC, on identifying its depth of invasion. METHODS: Endoscopic images of 40 EGC cases (20 showing positive non-extension sign on endoscopy as T1b2 and 20 showing negative non-extension sign on endoscopy as T1a-T1b1) were randomly displayed on PowerPoint. Participants read endoscopy findings (pretest) and attended a 60-min lecture on how to read the non-extension sign. Then, they read the same images using the non-extension sign as the marker (posttest). The primary endpoint was a change in accuracy rate for determining the depth of invasion before and after attending the lecture, for nonexperts (< 80%). RESULTS: Among 35 endoscopists, 12 were nonexperts; their test results were used for analyses. Accuracy rates for pretest and posttest among nonexperts were 75.2 and 82.5%, respectively, showing a significant increase in the accuracy rate after learning to read the non-extension sign (p = 0.003). CONCLUSION: Nonexperts' diagnostic ability to determine the depth of invasion of EGC improved by learning to read the non-extension sign. Thus, the non-extension sign is considered a simple and useful diagnostic marker.


Subject(s)
Clinical Competence/statistics & numerical data , Early Detection of Cancer/methods , Gastroenterologists/statistics & numerical data , Gastroscopy/statistics & numerical data , Stomach Neoplasms/diagnosis , Adult , Diagnostic Errors/prevention & control , Female , Gastric Mucosa/pathology , Gastroenterologists/education , Gastroscopy/education , Humans , Male , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Prospective Studies
20.
Digestion ; 101(5): 598-607, 2020.
Article in English | MEDLINE | ID: mdl-31302654

ABSTRACT

BACKGROUND/AIMS: To compare white light imaging (WLI) with linked color imaging (LCI) and blue LASER imaging (BLI) in endoscopic findings of Helicobacter pylori presently infected, previously infected, and uninfected gastric mucosae for visibility and inter-rater reliability. METHODS: WLI, LCI and BLI bright mode (BLI-bright) were used to obtain 1,092 endoscopic images from 261 patients according to the Kyoto Classification of Gastritis. Images were evaluated retrospectively by 10 experts and 10 trainee endoscopists and included diffuse redness, spotty redness, map-like redness, patchy redness, red streaks, intestinal metaplasia, and an atrophic border (52 cases for each finding, respectively). Physicians assessed visibility as follows: 5 (improved), 4 (somewhat improved), 3 (equivalent), 2 (somewhat decreased), and 1 (decreased). Visibility was assessed from totaled scores. The inter-rater reliability (intraclass correlation coefficient) was also evaluated. RESULTS: Compared with WLI, all endoscopists reported improved visibility with LCI: 55.8% for diffuse redness; LCI: 38.5% for spotty redness; LCI: 57.7% for map-like redness; LCI: 40.4% for patchy redness; LCI: 53.8% for red streaks; LCI: 42.3% and BLI-bright: 80.8% for intestinal metaplasia; LCI: 46.2% for an atrophic border. For all endoscopists, the inter-rater reliabilities of LCI compared to WLI were 0.73-0.87. CONCLUSION: The visibility of each endoscopic finding was improved by LCI while that of intestinal metaplasia was improved by BLI-bright.


Subject(s)
Gastric Mucosa/diagnostic imaging , Gastritis/diagnosis , Gastroscopy/methods , Image Enhancement/methods , Optical Imaging/methods , Adult , Aged , Aged, 80 and over , Color , Female , Gastric Mucosa/pathology , Gastritis/pathology , Gastroscopy/instrumentation , Gastroscopy/statistics & numerical data , Humans , Image Enhancement/instrumentation , Male , Metaplasia/diagnosis , Metaplasia/pathology , Middle Aged , Observer Variation , Optical Imaging/instrumentation , Optical Imaging/statistics & numerical data , Reproducibility of Results , Retrospective Studies , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL